Oxford begins trials for new HIV Vaccine

Oxford University has started its Phase I of a clinical trial to test the safety and efficacy of a new HIV Vaccine Candidate, called HIVconsvX.


The vaccine is designed to work on a variety of HIV-1 strains. At this stage in the trial, 13 healthy volunteers who are HIV negative will be given two doses, four weeks apart.


Most HIV vaccines in testing now work by stimulating the antibodies produced by B-cells, but this vaccine targets the T-cells, which grant a stronger immune system response and can destroy pathogens. The vaccine aims these potent cells at the areas of the highest HIV viral load.


Results from this trial are expected to be released within the next year.


Given that an HIV vaccine currently does not exist and the only existing options are to treat positive cases with antiretroviral therapies , a preventive vaccine could be ground breaking on a global scale. It is also hoped that an effective, safe vaccine might be able to inoculate people who are HIV positive and potentially cure them or at least prevent them from transmitting the virus.


Despite the effectiveness of antiretroviral therapies, a vaccine is still the best solution to stop the AIDS pandemic -- and since the earliest HIV outbreaks in the 80’s, a safe and effective vaccine has yet to be created.


This trial, the HIV-CORE 0052 trial, is being tested under the European Aids Vaccine Initiative, funded by the European Commission.


Want to Learn More?


In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient-perspective should be considered when designing studies to ensure that patient targets are met not only on time, but also on budget.


For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real time. The best part: these patients are already educated and prepared for the clinical trial process.


If you’d like to hear more about what we do, go here to read about what sets us apart, or here to read what our patients have to say about us.